Report ID: 10352322 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Europe monoclonal antibodies market was valued at $40.8 billion in 2020 and will grow by 11.0% annually over 2020-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 34 tables and 52 figures, this 110-page report “Europe Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.
Based on Source, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine
Based on Category, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs
Based on Production Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production
Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications
By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Europe Market by Source 41
3.1 Market Overview by Source 41
3.2 Human 43
3.3 Humanized 44
3.4 Chimeric 45
3.5 Murine 46
4 Segmentation of Europe Market by Category 47
4.1 Market Overview by Category 47
4.2 Branded mAbs 49
4.3 Biosimilar mAbs 50
5 Segmentation of Europe Market by Production Type 51
5.1 Market Overview by Production Type 51
5.2 In Vitro Production 53
5.3 In Vivo Production 54
6 Segmentation of Europe Market by Application 55
6.1 Market Overview by Application 55
6.2 Cancer 57
6.2.1 Breast Cancer 59
6.2.2 Colorectal Cancer 60
6.2.3 Lung Cancer 61
6.2.4 Ovarian Cancer 62
6.2.5 Other Cancer Types 63
6.3 Autoimmune Diseases 64
6.4 Inflammatory Diseases 65
6.5 Infectious Diseases 66
6.6 Other Applications 67
7 Segmentation of Europe Market by End User 68
7.1 Market Overview by End User 68
7.2 Hospitals 70
7.3 Research Institutes 71
7.4 Other End Users 72
8 European Market 2019-2030 by Country 73
8.1 Overview of European Market 73
8.2 Germany 76
8.3 U.K. 78
8.4 France 80
8.5 Spain 82
8.6 Italy 84
8.7 Russia 86
8.8 Rest of European Market 88
9 Competitive Landscape 90
9.1 Overview of Key Vendors 90
9.2 New Product Launch, Partnership, Investment, and M&A 93
9.3 Company Profiles 94
Abbott Laboratories 94
AbbVie, Inc. 96
Amgen Inc. 97
AstraZeneca plc 98
Bayer AG 99
Bristol-Myers Squibb Company 100
Eli Lilly 101
F. Hoffmann-La Roche Ltd. 102
GlaxoSmithKline Plc 103
Johnson & Johnson 104
Merck & Co., Inc. 105
Mylan N.V 106
Norvatis AG 107
Pfizer 108
Sanofi S.A. 109
RELATED REPORTS 110
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10352322 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
